KMT2A and leukemia: As KMT2A-r leukemia is driven by aberrant, oncogenic KMT2A fusion proteins that activate a hematopoietic stem cell-like transcriptional program by modifying the cell’s epigenome and chromatin structure (30), this leukemia subtype would in principle make an excellent target for drugs that affect chromatin organization.